Comments on: Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Accepted into European Medicines Agency’s PRIME Program

Comments on: Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Accepted into European Medicines Agency’s PRIME Program https://www.novumpr.nl/2016/06/02/biogens-investigational-alzheimers-disease-treatment-aducanumab-accepted-into-european-medicines-agencys-prime-program/?utm_source=rss&utm_medium=rss&utm_campaign=biogens-investigational-alzheimers-disease-treatment-aducanumab-accepted-into-european-medicines-agencys-prime-program NovumPR press releases Thu, 02 Jun 2016 13:05:49 +0000 hourly 1 https://wordpress.org/?v=6.8.2